The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Interim safety analysis of ALLG-Pacific: pembrolizumab plus R-CHOP as first-line therapy for PMBCL
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, introduces the ALLG-Pacific study (ACTRN12621001529831p), a Phase II investigator-initiated trial combining pembrolizumab with chemoimmunotherapy (R-CHOP) as first-line therapy for patients with primary mediastinal B-cell lymphoma (PMBCL). Dr Cheah highlights the study’s goal to improve outcomes for this rare and rapidly progressive subtype of diffuse large B-cell lymphoma (DLBCL), which primarily affects young women, and notes that the interim safety analysis showed no unexpected safety signals. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
